Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 and Humalog Across Different Subcutaneous Doses in Healthy Subjects

Trial Profile

A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 and Humalog Across Different Subcutaneous Doses in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 27 May 2021 Results of pooled analysis of 4 studies (NCT02942654, NCT03286751, NCT03166124, and NCT03305822) comparing and assessing the consistency of pharmacokinetics and glucodynamics between URLi and Humalog in healthy subjects and patients with T1D or T2D, published in the Clinical Pharmacokinetics.
    • 25 Sep 2020 Results of a pooled analysis of data pooled from 4 randomized trials (NCT02942654, NCT03305822, NCT03166124, NCT03286751) assessing the consistency of the pharmacokinetics and glucodynamics between URLi and Lispro in healthy subjects and patients with type 1 diabetes or type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 05 Sep 2020 Primary endpoint (Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC)) has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top